Physician profile
Walid Hafez
NPI 1902814957
$2,401.73
in general payments reported to CMS, 2019-2025
26 companies · $497 in 2025
The $497 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64.89 · 2021: $11.99 · 2022: $260 · 2023: $455 · 2024: $1,112 · 2025: $497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,064.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,064.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $564.63 | 2022-2025 | Wakix |
| Ucb, INC. | $277.97 | 2023-2025 | Nayzilam, Rystiggo, Fintepla |
| Pfizer INC. | $227.19 | 2024-2025 | |
| Amneal Pharmaceuticals LLC | $162.52 | 2023-2025 | Rytary, Crexont, Ongentys 50mg Capsules 30 |
| Lilly USA, LLC | $150.13 | 2023-2025 | Emgality, Kisunla, Reyvow |
| Alexion Pharmaceuticals, INC. | $146.09 | 2024-2025 | Ultomiris |
| Sk Life Science, INC. | $98.35 | 2024-2025 | |
| Argenx US, INC. | $97.49 | 2024-2025 | Vyvgart Hytrulo |
| Biogen, INC. | $91.81 | 2024-2025 | Skyclarys, Aduhelm, Tysabri |
| Abbvie INC. | $59.98 | 2022-2025 | |
| Celgene Corporation | $58.97 | 2021-2025 | Zeposia |
| Jazz Pharmaceuticals INC. | $55.23 | 2022 | |
| Genentech USA, INC. | $47.79 | 2024 | Ocrevus Zunovo, Ocrevus |
| Acadia Pharmaceuticals INC | $43.28 | 2024-2025 | Nuplazid |
| Tanabe Pharma America, INC. | $39.44 | 2023-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $39.27 | 2019 | |
| Novartis Pharmaceuticals Corporation | $32.47 | 2019-2023 | |
| Tg Therapeutics, INC. | $32.35 | 2025 | |
| Emd Serono, INC. | $32.10 | 2019-2024 | |
| Lundbeck LLC | $26.85 | 2024 | Vyepti |
| Neurocrine Biosciences, INC. | $24.13 | 2023 | Ongentys, Ingrezza |
| Alnylam Pharmaceuticals INC. | $20.14 | 2024 | Amvuttra |
| Janssen Biotech, INC. | $20.13 | 2025 | |
| Amgen INC. | $19.66 | 2025 | Uplizna |
| Immedica Pharma US, INC. | $17.85 | 2024 | |
| Eisai INC. | $15.91 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walid Hafez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.